• Genotyping Kit for Target Alleles: Streamlined PCR from Dive

  2026-04-20

  Unlock rapid, single-tube DNA extraction for insects, fish, tissues, and cells—eliminating time-consuming steps and minimizing contamination. APExBIO's Genotyping Kit for target alleles of insects, tissues, fishes and cells delivers robust, reproducible PCR-ready DNA to accelerate molecular biology genotyping research and genetic analysis across challenging sample types.

• Okadaic acid: Technical Use Guide and Workflow Parameters

  2026-04-19

  Okadaic acid is a potent inhibitor of protein phosphatase 1 (PP1) and 2A (PP2A), enabling precise modulation of phosphorylation-dependent signaling and apoptosis assays. This guide details validated protocol parameters, quality control steps, and troubleshooting for cell biology and biochemical research. It should not be used outside characterized PP1/PP2A inhibition contexts due to specificity and potency boundaries.

• S63845 MCL1 Inhibitor: Unveiling Apoptosis via Mitochondrial

  2026-04-18

  Explore how the S63845 MCL1 inhibitor serves as a mitochondrial apoptotic pathway activator in hematological cancer research. This article uniquely integrates recent scientific advances in mitochondrial membrane remodeling, offering a fresh perspective beyond standard apoptosis pathway analysis.

• Lamotrigine in Translational CNS Research: Permeability, Mec

  2026-04-17

  Explore how Lamotrigine, a leading sodium channel blocker, advances CNS research through deep analysis of blood-brain barrier permeability and translational assay design. This article uniquely contextualizes Lamotrigine’s mechanisms with cutting-edge model innovations.

• Doxorubicin: Mechanistic Insights and Strategy for Translati

  2026-04-16

  This article provides translational researchers with a comprehensive, mechanistic, and strategic perspective on Doxorubicin (Adriamycin), bridging core molecular mechanisms to workflow design and competitive positioning. Drawing on recent advances in apoptosis research and benchmarking within cancer chemotherapy, we explore how APExBIO’s Doxorubicin empowers next-generation oncology studies.

• Y-27632: ROCK Inhibitor for Cytoskeletal and Cancer Research

  2026-04-15

  Y-27632 is a benchmark ROCK inhibitor enabling precise modulation of cytoskeletal dynamics and advanced interrogation of cancer cell survival pathways. This guide delivers hands-on workflow enhancements, troubleshooting, and new insights linking cytoskeletal control to ribosome biogenesis and solid tumor therapy.

• Deep Learning Reveals USC Mitochondrial Changes as AD Biomar

  2026-04-14

  This study introduces a deep learning framework that analyzes mitochondrial morphology in urine-derived stem cells (USCs), enabling non-invasive detection of Alzheimer’s disease-related dysfunction. The work demonstrates robust AI-based discrimination of mitochondrial patterns in cognitively impaired individuals, offering a promising new biomarker approach.

• Captopril: Potent ACE Inhibitor for Hypertension Research

  2026-04-13

  Captopril is a benchmark ACE inhibitor with a validated IC50 of 6 nM, supporting both hypertension and cancer research. Its high purity and reproducible solubility parameters make it a preferred choice for translational studies. Recent evidence highlights its specific mechanistic action and emerging relevance in gastrointestinal models.

• DGLA-Induced Ferroptosis via ACSL4 in Acute Myeloid Leukemia

  2026-04-12

  This study demonstrates that exogenous dihomo-γ-linolenic acid (DGLA) can induce ferroptosis in acute myeloid leukemia (AML) cells through ACSL4-mediated lipid metabolic reprogramming. The findings reveal a potential therapeutic strategy for overcoming chemotherapy resistance in AML by targeting ferroptosis pathways.

• EdU Flow Cytometry Assay Kits (Cy3): High-Fidelity S-Phase A

  2026-04-12

  The EdU Flow Cytometry Assay Kits (Cy3) from APExBIO enable precise, denaturation-free detection of cell proliferation, streamlining DNA synthesis measurement in multi-parametric workflows. Leveraging click chemistry, these kits provide superior sensitivity and compatibility for advanced cell cycle and genotoxicity studies.

• SB 431542: ALK5 Inhibitor Workflows for TGF-β Signaling Stud

  2026-04-11

  SB 431542 is a gold-standard ALK5 inhibitor, empowering precise control of TGF-β signaling in cell-based and immunological research. This article delivers actionable protocols, advanced applications, and troubleshooting strategies, all underpinned by recent literature and validated product data.

• Dabigatran etexilate in Anticoagulant Research: Workflows an

  2026-04-11

  Dabigatran etexilate stands out as a robust oral direct thrombin inhibitor, offering superior experimental flexibility for studies in coagulation and atrial fibrillation. This guide details stepwise workflows, hands-on troubleshooting, and best-practice protocol parameters, positioning APExBIO’s Dabigatran etexilate as a foundational reagent for reproducible anticoagulant research.

• Mubritinib (TAK 165): Redefining Mitochondrial Inhibitors...

  2026-04-10

  Explore the advanced role of Mubritinib (TAK 165) as a selective mitochondrial electron transport chain complex I inhibitor in chemotherapy-resistant AML and PEL. This in-depth analysis uncovers novel mechanistic insights and translational research strategies for targeted cancer therapy.

• Mubritinib (TAK 165): Redefining Complex I Inhibition in ...

  2026-04-09

  Explore the unique mitochondrial mechanism of Mubritinib (TAK 165), a selective complex I inhibitor, and its transformative role in chemotherapy-resistant acute myeloid leukemia and primary effusion lymphoma research. This article provides technical depth and application strategies not found in existing resources.

• Optimizing Cell-Based Assays with Mubritinib (TAK 165): S...

  2026-04-08

  This article provides scenario-based guidance for biomedical researchers using Mubritinib (TAK 165, SKU B1543) in cell viability, proliferation, and cytotoxicity assays. Drawing on peer-reviewed data and best practices, we address common experimental challenges and highlight APExBIO’s Mubritinib as a reliable, high-performance reagent for mitochondrial complex I inhibition and chemotherapy-resistant cancer models.

406 records 18/28 page Previous Next First page 上5页 1617181920 下5页 Last page